Tiffany Khong


If you made any changes in Pure these will be visible here soon.

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 2016 2018

Augmented immune targeting of a myeloma-specific tumour antigen.

Shortt, J., Spencer, A., Reynolds, J., Johnstone, R. W., Quach, H., Grigoriadis, G., Kalff, A., Khong, T. T. F., Walker, P. & Powell, D. R.


Project: Research

Research Output 1999 2018

Open Access

Circulating tumour DNA analysis demonstrates spatial mutational heterogeneity that coincides with disease relapse in myeloma

Mithraprabhu, S., Khong, T., Ramachandran, M., Chow, A., Klarica, D., Mai, L., Walsh, S., Broemeling, D., Marziali, A., Wiggin, M., Hocking, J., Kalff, A., Durie, B. & Spencer, A. 1 Aug 2017 In : Leukemia. 31, 8, p. 1695-1705 11 p.

Research output: Contribution to journalArticleResearchpeer-review

β-catenin inhibitor BC2059 is efficacious as monotherapy or in combination with proteasome inhibitor bortezomib in multiple myeloma

Savvidou, I., Khong, T., Cuddihy, A., McLean, C., Horrigan, S. & Spencer, A. 1 Sep 2017 In : Molecular Cancer Therapeutics. 16, 9, p. 1765-1778 14 p.

Research output: Contribution to journalArticleResearchpeer-review

A rare case of IGH/MYC and IGH/BCL2 double hit primary plasma cell leukemia

Kalff, A., Khong, T., Wall, M., Gorniak, M., Mithraprabhu, S., Campbell, L. J. & Spencer, A. 2015 In : Haematologica: the hematology journal. 100, 2, p. e60-e62 3 p.

Research output: Contribution to journalLetterOtherpeer-review

Open Access

MDX-1097 induces antibody-dependent cellular cytotoxicity against kappa multiple myeloma cells and its activity is augmented by lenalidomide

Asvadi, P., Cuddihy, A. R., Dunn, R., Jiang, V., Wong, M. X., Jones, D. R., Khong, T. T. F. & Spencer, A. 2015 In : British Journal of Haematology. 169, 3, p. 333 - 343 11 p.

Research output: Contribution to journalArticleResearchpeer-review